USPTO Reaffirms Broad Institute’s CRISPR Patent Rights, Boosting Editas Medicine

The U.S. Patent and Trademark Office (USPTO) has reaffirmed its previous ruling in favor of the Broad Institute regarding the foundational patents for CRISPR/Cas9 gene editing. This decision confirms that the Broad Institute, which licenses its technology to Editas Medicine (EDIT), holds the priority for using CRISPR in eukaryotic cells, including human cells. The ruling concludes a protracted legal dispute with the CVC group, which includes the University of California and Nobel laureate Emmanuelle Charpentier. For Editas Medicine, this reaffirmation provides essential legal certainty and strengthens its intellectual property portfolio against industry rivals. While the decision is a continuation of a prior ruling, it solidifies the company's defensive position in the highly competitive biotech sector. Market analysts view this as a positive development for Editas, potentially impacting competitors like CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) who are aligned with the CVC group.

Sources:globenewswire.comnews.berkeley.edunationaltoday.comstocktitan.netbenzinga.comin.tradingview.comdrugpatentwatch.comtradingview.comgurufocus.com